Screener
Discontinued — last reported Q3 '25
CapEx at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed October 30, 2025.
- Filed
- Oct 30, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001438533-25-000056
| Line item | For the Nine Months Ended September 30, 2025 | For the Nine Months Ended September 30, 2024 |
|---|---|---|
| Cash Flows From Investing Activities: | ||
| Proceeds from the sale and maturity of marketable debt securities | 241,175 | 271,285 |
| Purchase of marketable debt securities | (69,217) | — |
| Purchase of fixed assets | (375) | (82) |
| Purchase of intangible assets | (38,918) | (26,569) |
| Other | 66 | — |
| Payment of milestone | — | (65,000) |
| Net cash provided by investing activities | 132,731 | 179,634 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s capex?
- Travere Therapeutics, Inc. (TVTX) reported capex of $140K in Q3 2025.
- What is the long-term trend for Travere Therapeutics, Inc.'s capex?
- Over 2 years (2021 to 2023), Travere Therapeutics, Inc.'s capex has grown at a -63.8% compound annual growth rate (CAGR), from $5.1M to $668K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Travere Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude